BioNTech Pays $205 Million for FDA Priority Review Voucher to Accelerate Late-Stage Oncology Drug Filing
By Dr. Zubair Khalid, DVM, MS, PhD ·
BioNTech has agreed to pay $205 million to purchase an FDA priority review voucher. The company plans to use the voucher to speed up a future regulatory filing for a drug in its late-stage oncology pipeline.
The voucher allows the holder to shorten the FDA’s standard review time for a new drug application from 10 months to six months. BioNTech has not yet specified which candidate will receive the voucher, but industry analysts point to the company’s most advanced oncology programs as likely contenders.
The transaction was disclosed in a regulatory filing. Priority review vouchers are transferable and can be bought and sold on the open market. BioNTech’s purchase is one of the largest sums paid for such a voucher to date.
Why this matters in life sciences
Priority review vouchers are a regulatory incentive originally created to encourage development of treatments for neglected tropical diseases. Companies that earn a voucher by gaining approval for a qualifying drug can sell it to another firm. The buyer gains faster FDA review, which can mean earlier market access and a competitive advantage. For BioNTech, the $205 million investment signals confidence in its late-stage oncology pipeline and reflects the high value the industry places on reducing regulatory timelines.
Source: original report